Page last updated: 2024-10-31

mitoxantrone and Vomiting

mitoxantrone has been researched along with Vomiting in 29 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.

Research Excerpts

ExcerptRelevanceReference
"A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis."9.09A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001)
"We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs."9.07[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993)
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)."9.05A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985)
"A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)."7.68Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991)
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose."7.67Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985)
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed."7.67[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984)
"Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia."7.67Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985)
"Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin."7.67Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987)
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i."7.67Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988)
"Forty-two women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione)."7.67Mitoxantrone as a first-line treatment of advanced breast cancer. ( Andersson, T; Borgstrom, S; Landys, K; Noppa, H, 1985)
"Congestive heart failure has been observed in one patient (doxorubicin)."6.66A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985)
"Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)."6.66Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985)
"Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity."5.27Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985)
"Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse."5.27Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987)
"A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis."5.09A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001)
"We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs."5.07[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993)
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)."5.05A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985)
" Prior to overt cerebral invasion by NHL, she had a thiamine deficiency with very low thiamine concentrations in the CSF, probably caused by protracted vomiting and increased vitamin B1 consumption by intrathecal tumor cells."3.70Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma. ( Boerman, RH; Mattijssen, V; Mulder, AH; Raemaekers, JM, 1999)
"A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)."3.68Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991)
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i."3.67Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988)
"Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia."3.67Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985)
"Forty-two women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione)."3.67Mitoxantrone as a first-line treatment of advanced breast cancer. ( Andersson, T; Borgstrom, S; Landys, K; Noppa, H, 1985)
"Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin."3.67Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987)
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose."3.67Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985)
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed."3.67[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984)
"Infections were the cause of death in nine patients, including four in the CMC5 group and five in the CMC3 group."2.70Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. ( Boguradzki, P; Błoński, JZ; Calbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, I; Kasznicki, M; Konopka, L; Kuliczkowski, K; Moskwa-Sroka, B; Nowak, W; Robak, T; Skotnicki, AB; Stella-Hołowiecka, B; Sułek, J; Wołowiec, D, 2001)
" Ten dogs were given mitoxantrone at a dosage of 5."2.67Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. ( Atwater, SW; Bergman, PJ; Chen, C; Ciekot, PA; Moore, AS; Ogilvie, GK; Walters, LM, 1994)
"Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies."2.67Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994)
"Thirty children with refractory acute lymphocytic leukemia (ALL) were treated with mitoxantrone, 8 mg/m2/day, for 5 days."2.67Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study. ( Estrada, J; Graham, ML; Ragab, AH; Rosen, D; Starling, KA; Wilkenson, RW; Wilkerson, RW, 1991)
" every 3 weeks in escalating doses combined with a fixed dose of s."2.67Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. ( Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F; Von Hoff, DD, 1991)
"Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity."2.66Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985)
"Congestive heart failure has been observed in one patient (doxorubicin)."2.66A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985)
"Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)."2.66Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985)
" Although the primary purpose of this study was to determine a clinically useful dosage and to characterize the toxicoses associated with mitoxantrone administration, each cat was monitored for response to treatment."1.29Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. ( Atwater, SW; Ciekot, PE; Elmslie, RE; Klein, MK; Moore, AS; Obradovich, JE; Ogilvie, GK; Salmon, MD; Straw, RC; Vail, DM, 1993)
"To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)."1.27Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). ( Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987)
"Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse."1.27Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987)
"Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity."1.27Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985)
"Ametantrone was extensively distributed (apparent volume of distribution, 26."1.27A phase I trial of ametantrone acetate (NSC-287513). ( Bender, JF; Gams, RA; Grillo-López, AJ; Ostroy, F, 1985)

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-199015 (51.72)18.7374
1990's11 (37.93)18.2507
2000's3 (10.34)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tominaga, T1
Kitamura, M1
Hayashi, K1
Takahashi, I1
Kosaki, G1
Sonneveld, P1
de Ridder, M1
van der Lelie, H1
Nieuwenhuis, K1
Schouten, H1
Mulder, A1
van Reijswoud, I1
Hop, W1
Lowenberg, B1
Ogilvie, GK3
Moore, AS3
Chen, C1
Ciekot, PA1
Atwater, SW2
Bergman, PJ1
Walters, LM1
Oza, AM1
ten Bokkel Huinink, W1
Dubbelman, R1
Soepenberg, O1
Mandjes, I1
Aartsen, E1
McVie, JG1
Obradovich, JE2
Elmslie, RE2
Vail, DM2
Straw, RC2
Salmon, MD1
Klein, MK1
Ciekot, PE1
Matsuishi, H1
Harada, M1
Gondo, H1
Otsuka, T1
Teshima, T1
Yamano, Y1
Omori, F1
Shibuya, T1
Yamazaki, K1
Taniguchi, S1
Mulder, AH1
Raemaekers, JM1
Boerman, RH1
Mattijssen, V1
Thurnher, D1
Kornfehl, J1
Burian, M1
Gedlicka, C1
Selzer, E1
Quint, C1
Neuchrist, C1
Kornek, GV1
Robak, T1
Błoński, JZ1
Kasznicki, M1
Góra-Tybor, I1
Dwilewicz-Trojaczek, J1
Boguradzki, P1
Konopka, L1
Ceglarek, B1
Sułek, J1
Kuliczkowski, K1
Wołowiec, D1
Stella-Hołowiecka, B1
Skotnicki, AB1
Nowak, W1
Moskwa-Sroka, B1
Dmoszyńska, A1
Calbecka, M1
van de Wyngaert, FA1
Beguin, C1
D'Hooghe, MB1
Dooms, G1
Lissoir, F1
Carton, H1
Sindic, CJ1
Gasparini, G1
Dal Fior, S1
Pozza, F1
Panizzoni, GA1
Favretto, S1
Von Hoff, DD2
Graham, ML1
Estrada, J1
Ragab, AH2
Starling, KA1
Rosen, D1
Wilkenson, RW1
Wilkerson, RW1
Samonigg, H1
Stöger, H1
Kasparek, AK1
Schmid, M1
Dusleag, J1
Pfeiffer, K1
Smola, M1
Steindorfer, P1
Lechner, P1
Curtis, CR1
Dickinson, K1
Cooper, MF1
Withrow, SJ1
Hiddemann, W1
Büchner, T1
Heil, G1
Schumacher, K1
Diedrich, H1
Maschmeyer, G1
Ho, AD1
Planker, M1
Gerith-Stolzenburg, S1
Donhuijsen-Ant, R1
Martoni, A2
Rani, P1
Ercolino, L1
Canova, N1
Pannuti, F2
Paciucci, PA1
Dutcher, JP1
Cuttner, J1
Strauman, JJ1
Wiernik, PH1
Holland, JF1
Steuber, CP1
Land, VJ1
Civin, CI1
Krischer, J1
Vietti, TJ1
Stewart, DJ1
Perrault, DJ1
Maroun, JA1
Lefebvre, BM1
Arlin, ZA1
Silver, R1
Cassileth, P1
Armentrout, S1
Gams, R1
Daghestani, A1
Coleman, M1
Schoch, I1
Dukart, G2
Posner, LE1
Goldberg, J1
Bernstein, T1
Cartwright, K1
Cowan, JD1
Osborne, CK1
Neidhart, JA1
Constanzi, JJ1
Vaughn, CB1
Bennett, JM1
Byrne, P1
Desai, A1
White, C1
DeConti, R1
Vogel, C1
Krementz, E1
Muggia, F1
Doroshow, J1
Plotkin, D1
Prentice, HG1
Wimperis, JZ1
Robbins, G1
Landys, K1
Borgstrom, S1
Andersson, T1
Noppa, H1
Mouridsen, HT1
Cornbleet, M1
Stuart-Harris, R1
Smith, I1
Coleman, R1
Rubens, R1
McDonald, M1
Rainer, H1
van Oosterom, A1
Smyth, J1
Metz, R1
Delgado, M1
Keiling, R1
Cappelaere, P1
Armand, JP1
Prevot, G1
Misset, JL1
Grimbert, J1
Mathe, G1
Periti, P1
della Cuna, GR1
Mazzei, T1
Preti, P1
Mini, E1
Gams, RA1
Ostroy, F1
Bender, JF1
Grillo-López, AJ1

Trials

13 trials available for mitoxantrone and Vomiting

ArticleYear
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:10

    Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined

1995
Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
    Journal of the American Veterinary Medical Association, 1994, Aug-15, Volume: 205, Issue:4

    Topics: Animals; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Follow-Up Studies; Leukocyte Count; Logi

1994
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:4

    Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito

1994
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyta

1993
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2001
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
    Leukemia, 2001, Volume: 15, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cohort Stud

2001
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
    Acta neurologica Belgica, 2001, Volume: 101, Issue:4

    Topics: Adult; Alopecia; Contrast Media; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans;

2001
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
    Investigational new drugs, 1991, Volume: 9, Issue:3

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation

1991
Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study.
    Investigational new drugs, 1991, Volume: 9, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Female; Humans;

1991
Mitoxantrone: an overview of safety and toxicity.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini

1985
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica

1985
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide;

1985
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone

1985

Other Studies

16 other studies available for mitoxantrone and Vomiting

ArticleYear
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8

    Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Mi

1984
Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
    Journal of the American Veterinary Medical Association, 1993, Jun-01, Volume: 202, Issue:11

    Topics: Animals; Anorexia; Carcinoma, Squamous Cell; Cat Diseases; Cats; Chemotherapy, Adjuvant; Dose-Respon

1993
Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma.
    Annals of hematology, 1999, Volume: 78, Issue:2

    Topics: Adult; Anisocoria; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bleomycin; Brain Neoplas

1999
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
    Cancer chemotherapy and pharmacology, 1991, Volume: 27, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi

1991
Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
    Journal of the American Veterinary Medical Association, 1991, May-01, Volume: 198, Issue:9

    Topics: Animals; Anorexia; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone;

1991
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Leukemia, 1990, Volume: 4, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation

1990
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1988, Volume: 7, Issue:5

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph

1988
Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
    Leukemia, 1987, Volume: 1, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Diarrhea; Drug Administrati

1987
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
    Investigational new drugs, 1987, Volume: 5, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Hea

1987
Combined mitoxantrone plus doxorubicin in the treatment of breast cancer.
    American journal of clinical oncology, 1987, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast

1987
Phase I-II trial of mitoxantrone in acute leukemia.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukem

1985
Mitoxantrone as a first-line treatment of advanced breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Cardiac Output; Female; Heart;

1985
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Ev

1985
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph

1985
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1985
A phase I trial of ametantrone acetate (NSC-287513).
    Investigational new drugs, 1985, Volume: 3, Issue:4

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Drug Administration Schedule; Drug

1985